Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis c-related cirrhosis

被引:150
|
作者
Pekow, Joel R.
Han, Atul K.
Zheng, Hui
Chung, Raymond T.
机构
[1] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA
[4] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA
关键词
hepatitis C virus; hepatocellular carcinoma; hepatc steatosis; cirrhosis;
D O I
10.1002/cncr.22701
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. Chronic hepatitis C can result in fatty changes in the liver. Previous studies have suggested that hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with hepatitis C virus (HCV) infection. The authors sought to determine whether hepatic steatosis is associated with hepatocellular carcinoma (HCC) in a cohort of patients with hepatitis C-related cirrhosis. METHODS. The authors retrospectively identified 94 consecutive patients with hepatitis C cirrhosis who underwent liver transplantation from 1992 to 2005 and had pathology available for review. Of these, 32 had evidence of HCC, and 62 had no HCC on explant histology. All explant specimens were graded again for steatosis bV a single, blinded pathologist. Steatosis, age, sex, body mass index, HCV RNA, HCV genotype, Model for End-Stage Liver Disease (MELD) score, chronic alcohol use, and diabetes were examined in univariate and multivariate analyses for association with HCC. RESULTS. In total, 69% of patients in the HCC group and 50% of patients in the control group had evidence of steatosis (1+) on histology. Odds ratios for the development of HCC for each grade of steatosis compared with grade 0 were as follows: grade 1 (1.61 [0.6-4.3]), grade 2 (3.68 (1.1-12.8]), and grade 3 or 4 (8.02 [0.6-108.31) (P =.03 for the trend). In univariate analysis, there was a significant association between increasing steatosis grade (P =.03), older age (56 years vs 49 years; P <.02), higher aspartate aminotransferase (122.5 U/L vs 91.5 U/L; P =.005), higher alanine amino transferase (95.8 U/L vs 57.2 U/L; P =.002), higher alpha- feto protein (113.5 ng/mL vs 17.8 ng/mL; P <.001), lower median HCV RNA (239,000 IU/mL vs 496,500 IU/mL; P =.02), higher biologic MELD score (21.8 vs 20.3; P =.03), and risk of HCC. In multivariate analysis, age (P =.02), AFP (P.007), and steatosis (P =.045) were significantly associated with HCC. CONCLUSIONS. in patients with HCV-related cirrhosis, the presence of hepatic steatosis is independently associated with the development of hepatocellular carcinoma. These findings suggest that steatosis poses an additional risk for HCC and that increased vigilance should be practiced in surveillance of persons with both HCV and steatosis.
引用
收藏
页码:2490 / 2496
页数:7
相关论文
共 50 条
  • [1] Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis
    Pekow, Joel
    Bhan, Atul K.
    Hui, Zheng
    Chung, Raymond T.
    GASTROENTEROLOGY, 2006, 130 (04) : A775 - A775
  • [2] No evidence for increased platelet activation in patients with hepatitis B- or C-related cirrhosis and hepatocellular carcinoma
    Alkozai, Edris M.
    Porte, Robert J.
    Adelmeijer, Jelle
    Zanetto, Alberto
    Simioni, Paolo
    Senzolo, Marco
    Lisman, Ton
    THROMBOSIS RESEARCH, 2015, 135 (02) : 292 - 297
  • [3] Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis
    D G Ward
    Y Cheng
    G N'kontchou
    T T Thar
    N Barget
    W Wei
    L J Billingham
    A Martin
    M Beaugrand
    P J Johnson
    British Journal of Cancer, 2006, 94 : 287 - 292
  • [4] Changes in the serum proteome associated with the development of hepatocellular carcinoma in hepatitis C-related cirrhosis
    Ward, DG
    Cheng, Y
    N'Kontchou, G
    Thar, TT
    Barget, N
    Wei, W
    Billingham, LJ
    Martin, A
    Beaugrand, M
    Johnson, PJ
    BRITISH JOURNAL OF CANCER, 2006, 94 (02) : 287 - 292
  • [5] Profiling of plasma metabolomics in patients with hepatitis C-related liver cirrhosis and hepatocellular carcinoma
    Nomair, Azhar Mohamed
    Madkour, Marwa Ahmed
    Shamseya, Mohammed Mohammed
    Elsheredy, Heba Gaber
    Shokr, Ahmed
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2019, 5 (04) : 317 - 326
  • [6] Surgical results in patients with dual hepatitis B- and C-related hepatocellular carcinoma compared with hepatitis B- or C-related hepatocellular carcinoma
    Chen, MF
    Jeng, LB
    Lee, WC
    Chen, TC
    SURGERY, 1998, 123 (05) : 554 - 559
  • [7] The role of serum visfatin and vaspin in hepatocellular carcinoma in hepatitis C-related liver cirrhosis
    Abdelhamed, Walaa
    Morsy, Khairy H.
    Hefny, Hesham M.
    Abudeif, Ahmed
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 210 - 220
  • [8] Surgical outcome in cirrhotic patients with hepatitis C-related hepatocellular carcinoma
    Hanazaki, K
    Wakabayashi, M
    Sodeyama, H
    Mochizuki, Y
    Machida, T
    Yokoyama, S
    Sode, Y
    Kawamura, N
    Miyazaki, T
    HEPATO-GASTROENTEROLOGY, 2000, 47 (31) : 204 - 210
  • [9] Levels of angiogenic proteins in plasma and platelets are not different between patients with hepatitis B/C-related cirrhosis and patients with cirrhosis and hepatocellular carcinoma
    Alkozai, Edris M.
    Porte, Robert J.
    Adelmeijer, Jelle
    Zanetto, Alberto
    Simioni, Paolo
    Senzolo, Marco
    Lisman, Ton
    PLATELETS, 2015, 26 (06) : 577 - 582
  • [10] Genomic risk of hepatitis C-related hepatocellular carcinoma
    Hoshida, Yujin
    Fuchs, Bryan C.
    Tanabe, Kenneth K.
    JOURNAL OF HEPATOLOGY, 2012, 56 (03) : 729 - 730